Purified CT (Sigma-Aldrich, St. Louis, USA) was administered as described previously 16, 35, with some modifications: 8 wk after transplantation, mice with

mLNtx or pLNtx were selleck products immunized orally with 10 μg of CT (in 50 μL of 0.01 M PBS containing 0.2% gelatine) on days 0, 8 and 14. On day 19, the mice were exsanguinated and cell suspensions were made (n=4–5). Analysis via flow cytometry was performed as described below. Eight wk after transplantation mice were fed with 25 mg OVA (Grade III; Sigma-Aldrich) in 200 μL PBS or PBS only as a control on day 0, 3, 6, and 8 by gavage. On day 16 mice were immunized by subcutaneous injection of 300 μg OVA (Grade VI; Sigma-Aldrich) in 200 μL PBS emulsified in complete Freud’s adjuvant (CFA; Sigma-Aldrich). On day 34 mice were challenged by subcutaneous selleck kinase inhibitor injection of 50 μg OVA (Grade VI) in 10 μL PBS into the right ear and PBS only into the left ear. Ear swelling was measured before challenge and 48 h later. DTH response was calculated as described previously

12. Based on the protocol for ot induction, tolerance in the periphery by the skin draining LN (pLN-pt) was induced as follows: 4.2 mg OVA (Grade III; Sigma-Aldrich) in 10 μL PBS or PBS only as a control on day 0, 3, 6 and 8 by subcutaneous injection into the forepaw of C57BL/6 mice. On day 16 mice were immunized by subcutaneous injection of 300 μg OVA (Grade VI; Sigma-Aldrich) in 200 μL PBS/CFA emulsion. On day 34 mice were challenged L-gulonolactone oxidase by subcutaneous injection of 50 μg OVA (Grade VI) in 10 μL PBS into the right ear and PBS only into the left ear. Ear swelling was measured before challenge and 48 h later and the DTH response was calculated. ot as well as pt were induced as described above. The mice were immunized by subcutaneous injection of OVA and CFA emulsion,

and on day 34 one group of mice was tested with the DTH reaction against OVA to verify that tolerance had been induced (n=3). The other mice were killed, the mLN or the pLN were removed and IgG+ cells or CD4+cells were isolated using the MACS technique following the instructions provided by Miltenyi (Bergisch-Gladbach, Germany). The purity of IgG+ cells was 90–97% and of CD4+ cells 90–93%. IgG+cells and CD4+ cells from mLN-ot or pLN-pt were injected intravenously (12–26×106 IgG+ cells/mouse; 7×106 CD4+ cells/mouse) into naïve wt mice. The recipients were immunized 1 day after cell transfer and the DTH response was measured 20 days later.